Fenofibrate
Brand names: Lipofen, Fenofibrate
At a glance
- Medicare prescriptions, 2024
- 1,520,963
- Medicare drug cost
- $42.2M
- Average cost per prescription
- $27.74
- Clinicians who prescribed it
- 55,129
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
LIPOFEN is indicated as adjunctive therapy to diet: to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL). to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible.
From the FDA-approved prescribing information (label dated May 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 36.2%
- Internal Medicine 27.4%
- Nurse Practitioners 17.2%
- Physician Assistants 5.0%
- Cardiology 4.1%
- General Practice 3.6%
- Endocrinology & Diabetes 1.8%
- Interventional Cardiology 1.4%
- Geriatric Medicine 1.0%
- Nephrology (Kidney) 0.4%
- Hospitalist 0.2%
- Infectious Disease 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 6% from 2019 to 2024.
Biggest change by state since 2019
- Idaho +14%
- Connecticut +12%
- Oklahoma +11%
- Delaware +8%
- South Dakota +8%
- Puerto Rico (smallest change) −22%
- West Virginia (smallest change) −21%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
A-S Medication Solutions
| Strength | Looks like | Imprint |
|---|---|---|
| 134 mg | white capsule, 19 mm | A318 |
Ani Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | white capsule, 16 mm | G 246 50 |
| 150 mg | white capsule, 19 mm | G 248 150 |
Apotex Corp.
| Strength | Looks like | Imprint |
|---|---|---|
| 43 mg | green capsule, 14 mm | APO F43 |
| 130 mg | green capsule, 19 mm | APO F130 |
Solco Healthcare US, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 48 mg | yellow oval tablet, 12 mm | 060 S |
| 145 mg | white oval tablet, 18 mm | 061 S |
Westminster Pharmaceuticals, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 54 mg | white oval tablet, 12 mm | CL 25 |
| 160 mg | white oval tablet, 18 mm | CL 26 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
3 recalls since 2020
- May 2026 · Ajanta Pharma USA Inc · Class II
CGMP Deviations - Mar 2025 · Glenmark Pharmaceuticals Inc., USA · Class II
CGMP Deviations - Mar 2021 · Cardinal Health Inc. · Class II
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.